| Display title | Chemistry:Sunepitron |
| Default sort key | Sunepitron |
| Page length (in bytes) | 4,562 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 807139 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>WikiG |
| Date of page creation | 15:07, 4 February 2023 |
| Latest editor | imported>WikiG |
| Date of latest edit | 15:07, 4 February 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Sunepitron (developmental code name CP-93,393) is a combined 5-HT1A receptor agonist and α2-adrenergic receptor antagonist. It was previously under development by Pfizer for the treatment of depression and anxiety. It made it to phase III clinical trials before being discontinued. |
